Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, August 11, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Emily Bodnar Reiterated (ACRV) at Strong Buy with Decreased Target to $20 on, Aug 11th, 2023
Emily Bodnar of HC Wainwright & Co., Reiterated "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy with Decreased Target from $21 to $20 on, Aug 11th, 2023.
Emily has made no other calls on ACRV in the last 4 months.
There are 2 other peers that have a rating on ACRV. Out of the 2 peers that are also analyzing ACRV, 0 agree with Emily's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Emily
- Matthew Biegler of "Oppenheimer" Initiated at Buy and Held Target at $25 on, Friday, June 2nd, 2023
- Etzer Darout of "BMO Capital" Initiated at Buy and Held Target at $25 on, Monday, May 8th, 2023
